Merck Isentress Gets Advisory Panel Support But May Get Narrow Indication
Executive Summary
Although divided on whether the indication for Merck's Isentress (raltegravir) should be narrowed, FDA's Antiviral Drugs Advisory Committee voted unanimously in favor of accelerated approval for the HIV drug on Sept. 5
You may also be interested in...
HIV Drug Development Guidance From FDA Stresses Clinical Resistance Testing
A finalized FDA guidance for antiretroviral drug development emphasizes HIV resistance testing and clinical analysis, rather than preclinical in vitro studies as outlined in the draft guidance. Templates for submitting resistance data on Hepatitis B and C virus also were dropped in the final version
HIV Drug Development Guidance From FDA Stresses Clinical Resistance Testing
A finalized FDA guidance for antiretroviral drug development emphasizes HIV resistance testing and clinical analysis, rather than preclinical in vitro studies as outlined in the draft guidance. Templates for submitting resistance data on Hepatitis B and C virus also were dropped in the final version
Merck’s Isentress – Is $27/Day A High Price To Pay For HIV Treatment?
Merck's first-in-class integrase inhibitor Isentress marks the firm's return to the HIV market, but also to the intense pricing scrutiny that surrounds AIDS products